Literature DB >> 22092733

Effects of ultraviolet radiation exposure on FOXP3+ infiltration in cutaneous squamous cell carcinoma and basal cell carcinoma.

Ling Chen1, Zhu Shen, Jinjin Wu.   

Abstract

PURPOSE: To analyze the prevalence and significance of FOXP3+ infiltration into (pre)malignant skin carcinomas following ultraviolet radiation (UVR) exposure. The possible pathways that UVR impacts on FOXP3 are to be discussed.
BACKGROUND: FOXP3+ regulatory T cells (FOXP3+ Tregs) are correlated to cutaneous squamous tumor progression. However, there is no information describing the prevalence of FOXP3+ infiltration in cutaneous premalignant and malignant squamous carcinomas with UVR exposure.
METHODS: We investigated the prevalence of FOXP3+ infiltration in 14 patients with Bowen's disease, 40 squamous cell carcinoma SCC patients and 21 patients with basal cell carcinoma (BCC) by immunohistochemistry.
RESULTS: The percentages of FOXP3+ vs. total peri-neoplasm infiltration cells (FOXP3+ PCT) were significantly higher in Bowen's disease and well-differentiated SCC that were exposed to UVR than these diseases not exposed to UVR (t = 3.5776, P = 0.0038; t' = 5.9214, P < 0.01, respectively). FOXP3+ PCT was also higher in less pigmented than pigmented sites in BCC (t = 3.369, P = 0.0032).
CONCLUSIONS: This study shed some light on the effect of UVR on FOXP3+ infiltration in skin (pre)malignant carcinomas. Our data suggested that FOXP3+ infiltration was positively related to UVR exposure. The mechanisms merit further investigation.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22092733     DOI: 10.1111/j.1600-0781.2011.00616.x

Source DB:  PubMed          Journal:  Photodermatol Photoimmunol Photomed        ISSN: 0905-4383            Impact factor:   3.135


  1 in total

1.  FOXP3 and CTLA-4 genetic variants' influence on the susceptibility and clinical course of basal cell carcinoma.

Authors:  Martyna Sławińska; Monika Zabłotna; Roman J Nowicki; Michał Sobjanek
Journal:  Postepy Dermatol Alergol       Date:  2020-02-27       Impact factor: 1.837

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.